For example, low VEGF(165)b:VEGF(total) ratio may be a predictive marker for bevacizumab in metastatic colorectal cancer [7], and individuals with high relative levels may not benefit from bevacizumab; low serum angiopoietin-2 (Ang-2), an inhibitory ligand of endothelial Tie-2 receptor, may be a predictive marker; and low serum neuropilin-1 (NRP-1) may predict better response and overall outcome of tivozanib, an oral VEGF TKI, or bevacizumab in combination with mFOLFOX6 [8]. Here, NRP1 is linked to metastatic colorectal cancer.